Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY...
NEWS RELEASE - REGULATED INFORMATION27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL,...
ZUG, Switzerland and BOSTON, Oct. 27, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
– Two Academic Powerhouses form Institut Pasteur-UCSF QBI Center of Excellence in Emerging Diseases with Planned Operations/Locations in San Francisco...
DUBLIN, Ireland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic...
BOTHELL, Wash., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the completion of enrollment in a...
Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023SAN...
WARMINSTER, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...
Study provides additional support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trialsBOSTON, Oct. 26, 2022 (GLOBE...
Amended Bridging Pharmacokinetics Study for Autosomal Dominant Polycystic Kidney Disease – XRx-008 ProgramCALGARY, Alberta, Oct. 26, 2022 (GLOBE NEWSWIRE) --...
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole...
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc....
BERKELEY HEIGHTS, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022ARLINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals,...
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive...
PTX-COVID19-B was well tolerated with no safety signalsNon-inferior neutralizing antibody titer levels versus comparator vaccine, Comirnaty®Providence will initiate a Phase...
BOTHELL, Wash., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam...
-- Data to be presented from CORAL-BOOST and CORAL-CEPI trials evaluating Gritstone’s samRNA vaccine candidates against SARS-CoV-2 -- EMERYVILLE, Calif.,...
Figure 1 SARS-COV-2 50% Tissue Culture Infectious Dose (TCID50) measurement in response to treatment with R327 in Syrian golden hamsters....
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing...